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(miRNAs as disease biomarkers) and miR-drugs (miRNAs 
as therapeutic targets) for cardiac ischemia and heart fail-
ure. Finally, we evaluate the use of miRNAs in the emerg-
ing field of regenerative medicine.
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Introduction
The impact of ischemic heart disease
Human heart disease remains the main cause of death and 
disability in children and adults in the developed coun-
tries. According to the American Heart Association [1], in 
every year since 1900 (except 1918) cardiovascular disease 
(CvD) accounted for more deaths than any other single 
cause in the United States, including cancer, chronic lower 
respiratory diseases, accidents, and diabetes mellitus. An 
expected 80,000,000 American adults (1 in 3) have one or 
more types of CvD. Among these, 7,900,000 are estimated 
to have an acute myocardial infarction (MI) [1]. This num-
ber keeps increasing despite the emphasis placed on pre-
vention and new therapeutic agents, rendering heart disease 
the health epidemic of the twenty-first century.
Ischemic heart disease is the most common underly-
ing cause of heart failure. Myocardial ischemia may arise 
from several aetiologies, the most prevalent being coro-
nary artery disease (CAD). Coronary artery disease causes 
severe impairment of the coronary blood supply and may 
lead to MI and heart failure. Resumption of blood flow in 
ischemic tissues, by coronary angioplasty or thrombolytic 
treatments, is currently recommended for the immediate 
early approach to acute MI. Reperfusion can clearly limit 
Abstract MicroRNAs (miRNAs) are natural, single-
stranded, small RNA molecules which subtly control gene 
expression. Several studies indicate that specific miRNAs 
can regulate heart function both in development and dis-
ease. Despite prevention programs and new therapeutic 
agents, cardiovascular disease remains the main cause 
of death in developed countries. The elevated number of 
heart failure episodes is mostly due to myocardial infarc-
tion (MI). An increasing number of studies have been car-
ried out reporting changes in miRNAs gene expression 
and exploring their role in MI and heart failure. In this 
review, we furnish a critical analysis of where the frontier 
of knowledge has arrived in the fields of basic and trans-
lational research on miRNAs in cardiac ischemia. we 
first summarize the basal information on miRNA biology 
and regulation, especially concentrating on the feedback 
loops which control cardiac-enriched miRNAs. A focus 
on the role of miRNAs in the pathogenesis of myocardial 
ischemia and in the attenuation of injury is presented. Par-
ticular attention is given to cardiomyocyte death (apopto-
sis and necrosis), fibrosis, neovascularization, and heart 
failure. Then, we address the potential of miR-diagnosis 
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the extent of cardiomyocyte loss. However, the resupply 
of blood may give rise to mitochondrial reactive oxygen 
species (ROS) and mitochondrial Ca2+ accumulation and 
finally elicit apoptotic pathways [2–4].
The complexity of microRNAs (miRNAs) biology
The pathogenesis of heart disease is often associated with 
the altered expression of pivotal specific genes [5]. A num-
ber of transcriptome studies have been applied to CvD, 
with the aim of improving diagnosis, prognosis, and thera-
peutic assessment [5–7]. Myocardial biopsies of patients 
suffering from acute/chronic myocardial ischemia, as well 
as animal models of ischemia and reperfusion (I/R), have 
revealed changes in gene expression which seem to be spe-
cific for the cardiac ischemic injury [8–10]. MicroRNAs 
(miRNAs) are important regulators of gene expression, 
constituting a major area of investigation in cardiovascu-
lar research [11]. MicroRNAs are a class of endogenous, 
non-coding RNA molecules of approximately 21 nucleo-
tides, which result from sequential processing of primary 
transcripts mediated by the RNase III enzymes, Drosha and 
Dicer. They post-transcriptionally regulate gene expres-
sion by means of an imperfect complementarity to the 3’ 
untranslated region of target mRNAs. The most stringent 
requirement for specifically targeting mRNAs is a contigu-
ous and perfect base-pairing of the miRNA’s nucleotides 
2–8 (seed sequence), which nucleates the interaction with 
the target messenger. MicroRNAs can regulate mRNA 
translation at the initiation, elongation, and termina-
tion process, or can affect mRNA stability. In eukaryotes, 
mRNA enzymatic degradation can follow two pathways, 
each of which is initiated by shortening of the mRNA 
poly-A tail [12]. Proteolytic cleavage of nascent polypep-
tides has also been described [13]. MicroRNAs may also 
act through mechanisms which go beyond complementa-
rity. Indeed, theycan regulate pre-mRNA processing in the 
nucleus, act as chaperones to modify structure, or modu-
late mRNA-protein interactions [13]. while miRNAs gen-
erally function in the cytoplasm, they can be imported in 
the nucleus [14], in the mitochondrium [15], and even be 
secreted from the cell [16] or transferred from one cell to 
another [17, 18]. Nevertheless, the relevance of subcellular 
localization for miRNA regulation is still a matter of study 
[19].
Currently, the estimated number of miRNA genes is as 
high as ~1,500 in the human genome (1–3 % of known 
genes are represented by miRNAs) and about 750 in the 
mouse [20], and they are supposed to regulate about 10,000 
target genes (excluding alternative splicing variants), which 
is 30 % of the coding genes [21]. Indeed, each miRNA is 
assumed to regulate tens to thousands of targets. Moreover, 
they most likely act as an ensemble (often synergistically). 
Indeed, “miRNAs working together” interact at the level 
of single targets, set of target genes, and complex systems 
[22]. Critically, miRNAs often attenuate the expression 
of their targets only moderately [23]. The network which 
derives is quite complex and many pieces in unravelling 
miRNAs biology are missing. Therefore, it is not surprising 
that the picture of miRNA regulation is still highly frag-
mented and sometimes incoherent, due to gaps in untan-
gling the coordinated action of such a number of molecules 
[13].
MicroRNAs in cardiovascular disease
Since miRNAs have proved to be key regulators of cardio-
vascular development [24], misregulation of miRNA func-
tion is likely to be involved in the onset of many human 
diseases, including CvD [25–28]. Since the initial impli-
cation of miRNAs in controlling heart development [29] 
and the identification of the pathological role of miRNAs 
during cardiac hypertrophy and failure [30–32], more than 
800 articles have been published examining miRNAs in the 
heart (more than 400 in 2012 alone). Recent studies have 
compared mRNA and miRNA expression profiles in the 
same myocardial samples obtained from patients suffering 
from heart failure, with or without mechanical left ventric-
ular assist device (LvAD) support. In contrast to mRNA, 
which varied moderately between the two groups, a spe-
cific set of miRNAs was significantly upregulated in heart 
failure and returned to normal in the LvAD recovery group 
[33, 34]. These findings suggest that miRNAs expression 
reflects the functional status of the heart more accurately 
than mRNAs.
In this review, we will briefly introduce muscle-specific 
miRNAs and describe the interplay occurring between 
miRNAs and their targets. Then, we will focus on miRNA 
regulation in cardiac ischemia. we will illustrate the role 
played by specific miRNAs in the different pathological 
aspects of myocardial ischemia: cardiomyocyte cell death, 
fibrosis, neovascularization, and heart failure. we will 
focus on the possible use of specific miRNAs as diagnos-
tic and prognostic biomarkers and as new potential targets/
tools for the treatment of heart disease. Finally, we will dis-
cuss the potential of miRNAs in the key promising field of 
regenerative medicine.
Feedback loops in the regulation of myomiRs
The myomiRs are a subset of miRNAs highly enriched in 
cardiac and/or skeletal muscle [35]. They include miR-
1, miR-133, miR-206 (present only in skeletal muscle), 
miR-208, miR-486, and miR-499 [36–38]. Several of 
these miRNAs are organized in bicistronic clusters on the 
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same chromosome (i.e. miR-1 and miR-133) and are tran-
scribed together [35]. Myogenic regulatory factors bind 
to upstream sequences and promote the transcription of 
these myomiRs in skeletal (MyoD, Myogenin) and cardiac 
(Mef2, Srf) tissues. The myomiRs, in turn, affect multiple 
developmental and functional aspects in both muscle and 
heart through the post-transcriptional regulation of genes 
controlling myogenesis [29, 39].
MyomiRs and myogenic factors are linked by reciprocal 
interactions, often based on the onset of feedback circuits. 
For example, a feedforward loop is established in skeletal 
muscle cells, where miR-1 derepresses the activity of Mef2 
through suppression of Hdac4. Activated Mef2, in turn, 
induces the expression of miR-1 [39]. Mef2 is also regu-
lated by miR-494. In myoblasts, miR-494 directly regulates 
mtTfa and Foxj3, which are upstream to Mef2. Mef2 pro-
motes the expression of mitochondrial proteins that, in turn, 
induce mtTfa [40]. Intriguingly, the presence of several 
myomiRs translocated from the cytosol to mitochondria 
has been demonstrated in human skeletal muscle cells [15]. 
Among these, miR-133 was predicted to target the mito-
chondrial NADH dehydrogenase subunit 1 and was impli-
cated in mitochondrial mRNA silencing [15]. The key role 
of miR-133 is further supported by the switch-off mecha-
nisms regulating its expression. In cardiac muscle cells, Srf 
regulates the expression of many miRNAs, including miR-
133 [29], which in turn represses expression of Srf [35, 41]. 
The tight modulation of forces driven by miR-1 and miR-
133 finally contributes to the balance between proliferation 
and differentiation in muscles [39].
Feedback regulatory loops also exist between myomiRs 
and intracellular signaling pathways. MiR-1 and miR-378 
are two representative examples. In fact, both the Met 
receptor and its ligand Hgf were identified as candidate 
targets of miR-1 [42]. Notably, Met is also downregulated 
by miR15b [43]. A reciprocal interplay between miR-1 and 
Met has been shown (in cancer), since miR-1 downregula-
tion results in Met overexpression and, in turn, Met nega-
tively controls miR-1 expression [44]. we have recently 
demonstrated the involvement of Met signaling in cardiac 
hypertrophy [45], and the importance of Hgf/Met axis in 
the response to MI is well documented [46]. It is there-
fore likely that a negative feedback loop is also established 
between miR-1 and Met in myocardial disease, constitut-
ing a circuit of potential therapeutic interest. Moreover, 
miR-1 targets Igf1 and Igf1 receptor (Igf1R). In turn, the 
Igf1 pathway downregulates miR-1 expression through the 
inhibitory phosphorylation, mediated by Akt, of Foxo3a, 
which directly acts on miR-1 promoter [47]. Through an 
analogous reciprocal control, miR-378 expression is inhib-
ited by Igf1 in cardiomyocytes [48].
The comprehension of the role and regulation of miR-
NAs during cardiac development, as well as in pathological 
conditions in the adult, constitutes the basis for new tar-
geted therapies for cardiac disease.
MicroRNAs in the attenuation of myocardial injury
The oxygen deprivation and ROS production which fol-
low cardiac ischemia and I/R cause cardiomyocyte cell 
death via both apoptosis and necrosis. Subsequently, car-
diac fibroblasts infiltrate the damaged tissue to increase the 
myocardial tensile strength by deposition of extracellular 
matrix. Finally, new blood vessels are formed in the border 
zone, resulting in partial restoration of blood supply. If the 
mechanisms aimed at attenuating injury are not sufficient, 
ultimately heart failure supervenes. In the following para-
graphs, the most interesting results on the role/regulation of 
miRNAs in these processes are reported and discussed in 
the view of possible therapeutic exploitations.
Cardiomyocyte cell death: apoptosis and necrosis
Ischemia and reperfusion are powerful inducers of cell 
death programs [49, 50]. The critical role of cardiac myo-
cytes death in the progression towards cardiac dilation 
and heart failure indicates that improvement of myocyte 
survival could represent an important therapeutic strategy. 
very few studies involve miRNAs in the autophagic death, 
in particular during I/R [51]. On the contrary, a large body 
of work suggests a role for miRNAs in the regulation of 
apoptosis (Fig. 1a). Intriguingly, miRNAs also regulate 
necrotic cell death.
A number of miRNAs exert an antiapoptotic function by 
targeting important proapoptotic proteins (Fig. 1a). miR-
499 and miR-30 family members diminish apoptosis in the 
injured heart by attenuating activation of dynamin-related 
protein-1 (Drp1) and thus inhibiting mitochondrial fission 
[52, 53]. Similarly, miR-24 and miR-21 inhibit cardiomyo-
cyte apoptosis [54, 55], via the repression of the proapop-
totic proteins Bim [54, 56] and programmed cell death 4 
(Pdcd4) [57, 58]. Interestingly, ex vivo miR-24 enrichment, 
together with miR-21 and miR-221, improves the therapeu-
tic potential of cardiacprogenitor cells upon transplantation 
in ischemic rodents [59]. Suppression of miR-24 increases 
cardiomyocytes apoptosis [60]. Nevertheless, miR-24 inhi-
bition is beneficial for angiogenesis (see below), raising 
some concerns about its therapeutic use. Notably, miR-24 
and miR-21 were shown to also reduce the rates of necro-
sis in ischemic cardiomyocyte cultures [56, 57]. Another 
important antiapoptotic miRNA is miR-210, which is con-
sidered the master hypoxamiR [61, 62]. In hypoxic cardio-
myocytes, miR-210 is upregulated by p53 in a Hif-depend-
ent, and by Akt in a Hif-independent way [63]. Increased 
survival of cardiomyocytes and of heart-engrafted bone 
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marrow-derived stem cells in the ischemic myocardium 
is promoted by miR 210 by targeting, respectively, Ptp1b 
and caspase-8-associated protein 2 [64, 65]. Furthermore, 
miR-210 regulates mitochondrial metabolism by targeting 
crucial proteins of the electron transport chain, at least in 
cancer cells [66–68]. miR-210 may also have a previously 
unrecognized role in the metabolic adaptation to hypoxic 
conditions in the infarcted myocardium.
On the other hand, a number of miRNAs have been 
shown to exert proapoptotic effects by targeting key cardio-
protective proteins (Fig. 1a), like, for example, heat-shock 
protein 20 (Hsp20), which is the target of miR-320 [69]. 
Among others, miR-34 family members promote growth 
arrest and apoptosis [70]. Indeed, therapeutic inhibition 
of miR-34 attenuates ischemia-induced remodeling and 
improves cardiac recovery [71]. A protein phosphatase 1 
nuclear targeting subunit (Pnuts) was identified as a novel 
miR-34 target [72].
Bcl2 family is a major hub on which multiple signals 
converge. Indeed, the proapoptotic miR-29 targets Mcl-1, 
a Bcl2 family-member [73]. In addition, targeting miR-15 
family members renders cultured cardiomyocytes resist-
ant to hypoxic death and ameliorates cardiac response 
to myocardial ischemia by inhibiting repression of Bcl2 
[74]. Finally, Bcl2, together with Hsp60 and Hsp70, is 
also the target of miR-1, which is upregulated in response 
to ischemic injury in vivo [75–77]. Akt signaling emerges 
as a further central node for improving cardioprotection 
against apoptosis and necrosis in myocardial ischemia and 
I/R. miR-1 as well as miR-378 both target the antiapoptotic 
IGF1 pathway [47, 48, 75] and are therefore involved in 
the apoptotic cell death induced by cardiac ischemia. How-
ever, the overexpression of miR-378 attenuates both apop-
tosis and necrosis in hypoxic cardiomyocytes by inhibiting 
caspase 3 [78]. Like miR-378, miR-494 lies at the edge 
between pro- and anti-apoptotic miRNAs, ultimately tilting 
the balance in favor of the activation of Akt [79].
Fibroblast proliferation and activation: fibrosis
Interstitial fibrosis is a major aspect of myocardial remod-
eling following MI, which contributes to loss of contrac-
tility and function. The extracellular deposition of collagen 
by fibroblasts contributes to this adverse remodeling after 
MI. Therefore, inhibiting fibroblasts proliferation, differen-
tiation, and secretion of matrix proteins may be clinically 
relevant for the prevention and treatment of heart failure 
after MI. Specific antifibrotic drugs are not currently avail-
able. Therefore, efforts should be focused on exploring new 
possible therapeutic targets.
Interestingly, an anti-miR-21 was shown to prevent 
myocardial fibrosis in a model of pressure overload [80]. 
Indeed, miR-21 represses the expression of Sprouty, a neg-
ative regulator of Mapk, thus enhancing proliferation of 
fibroblasts [80, 81] (Fig. 1b). Moreover, miR-21-dependent 
targeting of sprouty homolog 1 (Spry1) and Pdcd4 was 
shown to promote the fibroblastoid phenotype in epicardial 
mesothelial cells undergoing epithelial-to-mesenchymal 
transition [82]. Moreover, phosphatase and tensin homo-
logue (Pten) is a direct target of miR-21 [83] in cardiac 
Fig. 1  Target mRNAs and 
functional role of miRNAs 
related to myocardial ischemia 
in cardiomyocytes (a), fibro-
blasts (b), and endothelial cells 
(c). Arrows and bars at the end 
of the lines indicate whether 
the target is activated (arrow) 
or inhibited (bar). Dotted 
pink- and light blue-shaded 
regions indicate, respectively, 
stimulation or repression of a 
process (apoptosis, fibrosis, and 
angiogenesis) in myocardial 
ischemia
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fibroblasts. Pten upregulates the expression of matrix met-
alloproteinase 2 (Mmp2), promoting fibrosis in the 
infarcted heart. However, opposite results were obtained by 
Olson’s group [84], leaving still debated whether targeting 
miR-21 in the heart may be beneficial for the treatment of 
myocardial ischemia and infarction.
On the other hand, miR-133, miR-1, miR-30, and miR29 
family members directly (or indirectly in the case of miR-
711, which targets Sp1) downregulate key profibrotic pro-
teins [85–88] (Fig. 1b). In particular, miR-29 family mem-
bers are downregulated in the infarct area [86] and during 
collagen accumulation upon experimental fibrosis [89], 
while elevated miR-29 levels and repressed collagen syn-
thesis follow stimulation with HGF [90], a powerful antifi-
brotic factor [46]. However, the proapoptotic effect exerted 
by miR-29 on cardiomyocytes generates an important criti-
cism in the therapeutic use of miR-29 to reduce fibrosis in 
MI.
A major pathway implicated in cardiac fibrosis involves 
Tgf-β, which induces fibroblasts to synthesize and contract 
extracellular matrix. MicroRNAs targeting the Tgf-β path-
way may offer a therapeutic tool to interfere with fibrosis 
following MI. In this respect, miR-21 has been proposed as 
a regulator of Tgf-β pathway. while inducing the prolifera-
tion of fibroblasts, miR-21 simultaneously increases matrix 
deposition. Notably, miR-21 itself is upregulated by Tgf-β 
[91]. Also, miR-24 and miR-101 have been suggested to 
influence Tgf-β pathway. Upregulation of miR-24, which is 
downregulated in MI heart, can reduce fibrosis by decreas-
ing differentiation and migration of cardiac fibroblasts 
through the control of Tgf-β activation [92]. Overexpres-
sion of miR-101 suppresses both proliferation and collagen 
deposition in cardiac fibroblasts, resulting in inhibited post-
infarct cardiac fibrosis and improved cardiac function in 
vivo, by targeting the Tgf-β pathway [93].
endothelial cells proliferation and migration: 
neovascularization
Neoangiogenesis mainly occurs in the MI border zone to 
sustain cardiomyocytes survival and repair with oxygen 
and nutrients. A number of miRNAs are involved in vas-
cular biology [94]. The most convincing evidence for the 
participation of miRNAs in the angiogenic response to 
myocardial ischemia concerns the proangiogenic miR-126, 
miR-1, and miR-210, and the antiangiogenic miR-92a, 
miR-24, and miR-214 (Fig. 1c).
MiR-126 is upregulated in the border zone of MI [95]. 
Consistently, neovascularization after MI is inhibited in 
miR-126 knockout mice [95]. The proangiogenic effect of 
miR-126 following myocardial infarction has been attrib-
uted to the repression of Spred-1 [95], an intracellular 
negative regulator of Mapks (Fig. 1c). Targeting of Spred1 
leads to the increase in vascular endothelial growth factor 
(vegf), favoring proliferation and migration of endothelial 
cells. Notably, miR-1 has also been recently shown to target 
Spred-1 [96], thus suggesting that the activation of Mapks 
in endothelial cells is a hub for the convergence of proan-
giogenic miRNA stimuli. Mesenchymal stem cells [97, 98] 
and endothelial progenitors [99] transduced with miR-126 
have been proposed as a novel therapeutic approach for 
the improvement of post-ischemic angiogenesis. Finally, 
intramyocardial injection of a non-viral vector minicircle 
DNA carrying the miR-210 precursor reduces infarct size 
by enhancing angiogenesis [64], through the downregula-
tion of ephrin-A3 (efna3) [62]. Thus, delivery of proan-
giogenic miR-126 and miR-210 might be considered as a 
therapeutic approach in ischemic heart disease.
Conversely, miR-92a, miR-24 and miR-214 suppress 
neovascularization in myocardial infarction by inhibition of 
proangiogenic proteins, such as α5 integrin (Itga5) [100], 
Gata2 and Pak4 [101], and Quacking [102], respectively 
(Fig. 1c). Accordingly, blocking of miR-24 limits myocar-
dial infarct size in mice [101] and increases angiogenesis 
and blood perfusion in the peri-infarct myocardium, by 
prompting endothelial cells survival, proliferation, and net-
working in capillary-like tubes [60].
Other miRNAs, such as miR-130, miR-320, miR-
221/222, miR-296, and miR-378 have been shown to 
regulate physiological vascular function and tumor angio-
genesis [36]. However, a function in the regulation of angi-
ogenesis in cardiac ischemia has not yet been investigated.
MicroRNAs in heart failure
Ischemic cardiomyopathy is a common cause of conges-
tive heart failure. In hypoxic conditions, the heart reacti-
vates a fetal gene program, involving extensive remodeling, 
decreased aerobic metabolism, and increased cardiac effi-
ciency. Among others, the fetal isoform of myosin heavy 
chain (β-MHC) and the natriuretic factor genes are invari-
ably upregulated in the failing heart. However, this adap-
tive response is the first step of the subsequent heart failure. 
A subset of miRNAs which are up- and downregulated in 
experimental heart failure [31] are also modulated in failing 
human hearts [31, 103–106]. A number of miRNAs have 
been shown to be either upregulated (miR-21, miR-29b, 
miR-129, miR-210, miR-211, miR-212, miR-423, miR-199 
family, miR-379, miR-503, and miR34b and c) or down-
regulated (miR-30, miR-182, and miR-526) [106, 107]. 
Consistent with the reexpression of the fetal gene program, 
a high degree of similarity was found between the miRNA 
expression patterns occurring in human failing hearts and 
those observed in human fetal hearts, thus indicating that a 
fetal miRNA program is also reactivated by cardiac stress 
[106].
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Besides reactivation of fetal miRNAs and genes, 
impaired Ca2+ homeostasis is a hallmark of failing hearts. 
Myocardial sarcoplasmic reticulum Ca2+ ATPase 2a (SeR-
CA2a) is downregulated in heart failure and SeRCA2a 
gene therapy improves cardiac function in both animals 
and patients [108]. Intriguingly, miR-1 is downregulated in 
heart failure and SeRCA2a gene therapy is able to restore 
miR-1 expression in heart failure via an Akt/Foxo3a-
dependent pathway [109]. Notably, in the adult heart, both 
miR-1 and miR-133, which are in the same bicistronic unit, 
display an anti-hypertrophic activity [110, 111]. These 
data might encourage the use of miR-1 for treating myo-
cardial ischemia; however, the negative effects exerted on 
cardiomyocytes survival might hamper any other beneficial 
effect.
The abnormal increase in intracellular Ca2+ observed 
during myocardial reperfusion is a major concern. In fact, 
it is thought to be the cause of cardiomyocyte death and 
consequent loss of cardiac function, leading to heart fail-
ure. Indeed, therapeutic miRNA-mediated modulation of 
Ca2+ handling may provide some cardioprotection against 
the paradoxical effects of reperfusion. In this respect, it 
was shown that miR-214 is upregulated during ischemic 
injury and heart failure [112], and that genetic deletion of 
miR-214 in mice worsens the heart response to I/R. The 
cardioprotective role of miR-214 during I/R injury is most 
likely due to the repression of sodium/calcium exchanger 
1, a key regulator of Ca2+ influx, and to the repression of 
downstream apoptotic and necrotic effectors of Ca2+ sign-
aling [112]. Among these, CaMKIIδ is a common target of 
both miR-214 and miR-145 [113]. MiR-145 concomitantly 
protects cardiomyocytes from ROS by targeting Bnip3 
[114]. Boosting miR-214 and miR-145 levels to attenuate 
Ca2+ overload and cardiac cell death may provide a valu-
able therapeutic benefit for the treatment or prevention of 
heart failure after I/R injury. However, some caution must 
be adopted, due to the antiangiogenic effects of miR-214, 
which reduces sprouting of endothelial cells by targeting 
Quacking [115].
Future directions for therapy
miR-diagnosis and miR-drugs
The discovery of specific miRNAs as important regulators 
of the cardiac response to ischemia has opened new per-
spectives for clinical research. Recent results obtained in 
cancer suggest that the profiles of blood circulating miR-
NAs might mirror the changes observed in the cancerous 
tissue [116]. This concept has also proved valid in heart 
failure [117], and the significance of circulating miRNAs 
in comparison to conventional biomarkers has just begun 
to be investigated in the cardiovascular field [118, 119]. 
Circulating cardiac miRNAs are indeed released as a spe-
cific response to myocardial injury and can be used in the 
diagnosis of MI [120–124]. Recently, it was discovered that 
most of the extracellular miRNAs circulate in the blood of 
both healthy and diseased patients as secretory molecules, 
contained in apoptotic bodies, microvesicles, and exosomes 
or bound to RNA-binding proteins [16]. New challenges 
for miRNA biology include unraveling the secretory mech-
anism, as well as the significance and biological function 
of extracellular miRNAs. Moreover, large sample sizes are 
required to give an accurate estimate of the diagnostic and 
prognostic utility of miRNAs as CvD biomarkers. New 
frontiers are expected to be delineated for miR-diagnosis.
As important regulators of heart function, miRNAs rep-
resent attractive targets/tools for treating heart disease with 
miR drugs [125–131]. The momentum in miRNA field is 
hyped by the large investment announced by the Colorado-
based Miragen, which will initially focus on identifying 
targets related to CvD, primarily heart failure. A number 
of in vivo pre-clinical studies have been conducted using 
anti-miRNAs strategies, such as antagomiRs, 2’O-methyl-
modified cholesterol-conjugated single-strand RNA oligos 
with perfect complementarity to target miRNAs. Treatment 
with antagomiRs in mice has been used to prove the role 
of specific miRNAs in determined phenotypes [69, 111]. 
For example, a miR-21-directed antagomiR has been used 
to prevent myocardial fibrosis after pressure overload [80]. 
It must be noted that miR-21 is expressed in a broad array 
of tissues, including the vasculature, thus making the dis-
crimination between primary and secondary cardiac effects 
induced by intravenous injection of the antagomiR difficult. 
The use of highly tissue-specific adeno-associated viral 
vectors should be taken into account in order to improve 
delivery and specificity. In this perspective, AAv9 might 
represent the best choice for cardiac interventions [132]. 
Mimics of angiomiRs (or antagomiRs of anti-angiomiRs) 
might also be used to improve neoangiogenesis in cardiac 
ischemia [64, 95].
Another intriguing therapeutic approach might be the 
use of miRNAs in preconditioning. Indeed, it is possible 
to stimulate the intrinsic resistance to hypoxia through 
repeated short episodes of ischemia. During normoxia, 
Hif1α is targeted by miR-199a, while, during hypoxia, 
miR-199a is downregulated (by a still undefined post-tran-
scriptional mechanism), thus contributing to the expression 
of Hif1α [133]. The therapeutic knockdown of miR-199a 
during normoxia might therefore be used to mirror hypoxic 
preconditioning and protect cardiomyocytes against sub-
sequent hypoxic damage, as suggested by recent results 
[134].
The drugs which are typically administered to treat heart 
failure mostly aim at reducing blood pressure and improve 
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heart pumping. The rapid advancement in the identification 
of new miRNAs associated with heart failure will certainly 
increase our arsenal for the treatment of such a threatening 
disease.
MicroRNAs and regenerative applications
Regeneration of an injured heart can be carried out by 
new muscle cells coming from two sources: replication of 
preexisting cardiomyocytes and expansion, followed by 
proper differentiation of stem cells or precursors (resident 
or injected). The field of regenerative medicine is expand-
ing. The exploitation of miRNAs to this purpose is a certain 
target for future research.
Reactivation of cardiomyocytes proliferation
In mammals, the transition from the proliferative to the 
hypertrophic phenotype is strictly regulated [135]. In the 
neonate, 3–15 % of the cardiomyocytes are still cycling 
[136–138]. However, cardiomyocyte proliferation declines 
after birth [139]. After cardiac injury, a low level of cardio-
myocyte replication occurs, suggestive of a partial attempt 
of the myocardium to regenerate [140–143]. Nevertheless, 
the proliferative capacity of adult cardiomyocytes is limited 
and insufficient to replace the ≈1 billion cardiomyocytes 
typically lost in MI. Recent studies have provided evidence 
for supporting therapeutic reactivation of cardiomyocyte 
proliferation by means of miRNAs.
MiR-15 family has an important role in governing car-
diomyocyte cell cycle withdrawal. During neonatal devel-
opment, miR-15 family is upregulated in the heart, in 
concomitance with the irreversible exit of cardiomyocytes 
from the cell cycle [144]. Consistently, post-natal knock-
down of miR-15 family members through in vivo delivery 
of anti-miR oligonucleotides has been associated with an 
increased number of mitotic cardiomyocytes [144]. Moreo-
ver, overexpression of miR-195 (member of miR-15 fam-
ily) in the neonatal heart reduced the regenerative potential 
after myocardial ischemia [145].
Also, the depletion of miR-133 (which has an impor-
tant role in the proliferation and differentiation of cardiac 
progenitors during cardiomyogenesis [29, 146]), enhances 
the cardiac regenerative responses in zebrafish cardio-
myocytes after injury [147]. Indeed, cardiac regeneration 
in zebrafish, albeit unclear, appears to be at least partially 
based on cardiomyocyte proliferation [148–150]. In con-
trast, transgenic overexpression of miR-17-92 in cardio-
myocytes is sufficient to induce cardiomyocyte prolifera-
tion in embryonic, post-natal, and adult hearts. Moreover, 
overexpression of miR-17-92 in adult cardiomyocytes 
protects the heart from myocardial infarction-induced 
injury [151].
The recent publication from eulalio et al. [152] pro-
duced excitement and open questions [153, 154]. Giacca’s 
group has shown that hsa-miR-590 and hsa-miR-199a can 
trigger cell cycle reentry of adult cardiomyocytes ex vivo 
and promote cardiomyocyte proliferation in both neonatal 
and adult animals. when these miRNAs are administered to 
ischemic hearts, they induce the replication of cardiomyo-
cytes and stimulate repair of damage through the formation 
of new heart cells [152].
These observations hint at the possibility of identifying 
and targeting the molecular regulators that maintain cardio-
myocytes in the quiescent state after injury. However, care 
must be taken in forcing cell cycle progression in cardio-
myocytes, since these may undergo hypertrophy or apopto-
sis, both detrimental to cardiac function [139, 155]. Thus, 
therapeutic strategies aimed at stimulating cardiomyocyte 
proliferation should require the concomitant expression 
of cell cycle regulators and cardioprotective molecules to 
ensure full activation of the cell cycle and protection from 
apoptosis. In this sense, the peculiar capacity of miRNAs to 
exert multiple coordinate effects represents a clear advan-
tage in preventing catastrophic mitosis.
Stimulation of cardiac progenitors
The identification of cardiac cells with stem cell properties 
changed the paradigm of the heart as a post-mitotic organ 
[156–158]. These cells proliferate and differentiate into 
cardiomyocytes and endothelial and vascular smooth mus-
cle cells, providing for cardiac homeostasis and regenera-
tion. However, the regenerative potential of resident cardiac 
progenitors is limited. Some recent reviews extensively 
explored the possibility of manipulating this regenera-
tive potential by the use of miRNAs [153, 154, 159, 160]. 
Indeed, miRNAs act as regulators of proliferation and dif-
ferentiation of adult cardiac stem cells and progenitors [39, 
161–164].
The use of exogenous stem cells for cellular therapy 
constitutes a major avenue of investigation [158]. The 
potential of miRNAs in stimulating expansion and differen-
tiation of embryonic and induced pluripotent stem cells has 
been reviewed extensively elsewhere [153]. Survival and 
functional integration of transplanted cells as well as their 
proper differentiation are major concerns to improve car-
diac function. Indeed, one of the major hurdles to achieve 
long-term improvement of heart function through stem cell 
therapies is the low survival rate of the injected stem cells 
in the hostile environment of the damaged myocardium. A 
miRNA cocktail has recently been shown to increase via-
bility of transplanted cells in the infarcted heart by target-
ing Bim and, thus, induce better recovery [59].
An important regulator of cardiac progenitor cells 
(CPCs) differentiation is miR-499. Although barely 
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detectable in undifferentiated precursors, it is strongly 
induced in post-mitotic cardiomyocytes. In human CPCs, 
miR-499 enhances cardiogenesis by repressing Sox6 and 
Rod1. Importantly, CPCs overexpressing miR-499 have 
increased potential to regenerate the damaged myocardium 
in an animal model of myocardial infarction [17].
Notably, miRNAs can act as paracrine messengers. For 
example, miR-499 has been shown to traverse gap junc-
tion channels and translocate to structurally coupled CPCs 
favoring their differentiation into functionally competent 
cells [17]. An inverse flux of miR-210 from transplanted 
stem cells of mesenchymal origin to host cardiomyocytes 
has been shown to functionally recover the ischemic heart, 
meanwhile promoting post-engraftment survival [18].
Conclusions and take‑away message
Many miRNAs have been implicated in the control of car-
diac apoptosis, fibrosis, and neovascularization following 
myocardial ischemia and I/R injury and in the adaptation of 
the heart to damage. Therefore, analyzing (miR-diagnosis) 
and manipulating (miR-drugs) miRNA biology represents 
an attractive, albeit ambitious, approach for diagnosis and 
therapeutics. Moreover, new evidence supports a role for 
miRNAs in the induction of proliferation of cardiomyocytes 
and improvement of survival, renewal, and differentiation 
of precursor and stem cells. One major advantage in using 
miRNAs is certainly the possibility to simultaneously target 
multiple proteins and even entire pathogenic pathways. The 
main problem is to globally obtain a coherent and benefi-
cial effect. Indeed, in some cases, this huge potential might 
represent a double-edged sword. As emerges from Table 1, 
some miRNAs exerting a positive effect on one particular 
cell type might simultaneously have a deleterious influence 
on another cardiac cell population. The outbalancing force 
should therefore be identified with caution. Indeed, such a 
spectrum of actions implicates the need for a comprehensive 
knowledge of miRNAs networks and interplay in order to 
predict (and prevent) possible side effects.
Acknowledgments This work was supported by funds from the 
Association Francaise contre les Myopathies (AFM) to T.C. This 
work and a fellowship to v.S. were made possible by eU grant FP7-
SST 265772 eM-Safety to A.P.
References
 1. Roger vL, Go AS, Lloyd-Jones DM, Benjamin eJ, Berry JD, 
Borden wB et al (2012) Heart disease and stroke statistics-2012 
update a report from the American Heart Association. Circula-
tion 125:e2–e220
 2. Buja LM, weerasinghe P (2010) Unresolved issues in myocar-
dial reperfusion injury. Cardiovasc Pathol 19:29–35
 3. de Groot H, Rauen U (2007) Ischemia-reperfusion injury: 
processes in pathogenetic networks: a review. Transpl Proc 
39:481–484
 4. Frangogiannis NG (2012) Regulation of the inflammatory 
response in cardiac repair. Circ Res 110:159–173
 5. Nanni L, Romualdi C, Maseri A, Lanfranchi G (2006) Differen-
tial gene expression profiling in genetic and multifactorial car-
diovascular diseases. J Mol Cell Cardiol 41:934–948
 6. Huang XH, Pan w, Grindle S, Han XQ, Chen YJ, Park SJ et al 
(2005) A comparative study of discriminating human heart fail-
ure etiology using gene expression profiles. BMC Bioinform 
6:205–218
 7. Sanoudou D, vafiadaki e, Arvanitis DA, Kranias e, Kontrogi-
anni-Konstantopoulos A (2005) Array lessons from the heart: 
focus on the genome and transcriptome of cardiomyopathies. 
Physiol Genomics 21:131–143
 8. Gabrielsen A, Lawler PR, wang YZ, Steinbruchel D, Blagoja D, 
Paulsson-Berne G et al (2007) Gene expression signals involved 
in ischemic injury, extracellular matrix composition and fibrosis 
defined by global mRNA profiling of the human left ventricular 
myocardium. J Mol Cell Cardiol 42:870–883
 9. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, edness G, 
Breton e et al (2005) Gene expression analysis of ischemic 
and nonischemic cardiomyopathy: shared and distinct genes 
in the development of heart failure. Physiol Genomics 
21:299–307
 10. Prat-vidal C, Galvez-Monton C, Nonell L, Puigdecanet e, Ast-
ier L, Sole F et al (2013) Identification of temporal and region-
specific myocardial gene expression patterns in response to 
infarction in swine. PLoS ONe 8:e54785
 11. Mendell JT, Olson eN (2012) MicroRNAs in stress signaling 
and human disease. Cell 148:1172–1187
 12. Parker R, Song Hw (2004) The enzymes and control of eukary-
otic mRNA turnover. Nat Struct Mol Biol 11:121–127
 13. Filipowicz w, Bhattacharyya SN, Sonenberg N (2008) Mecha-
nisms of post-transcriptional regulation by microRNAs: are the 
answers in sight? Nat Rev Genet 9:102–114
 14. Hwang Hw, wentzel eA, Mendell JT (2007) A hexanucleotide 
element directs microRNA nuclear import. Science 315:97–100
 15. Barrey e, Saint-Auret G, Bonnamy B, Damas D, Boyer O, 
Gidrol X (2011) Pre-microRNA and mature microRNA in 
human mitochondria. PLoS ONe 6:e20220
 16. Kosaka N, Ochiya T (2011) Unraveling the mystery of can-
cer by secretory microRNA: horizontal microRNA transfer 
between living cells. Front Genet 2:97
 17. Hosoda T, Zheng HQ, Cabral-da-Silva M, Sanada F, Ide-
Iwata N, Ogorek B et al (2011) Human cardiac stem cell dif-
ferentiation is regulated by a mircrine mechanism. Circulation 
123(12):1287–1296
 18. Kim Hw, Jiang SJ, Ashraf M, Haider KH (2012) Stem cell-
based delivery of Hypoxamir-210 to the infarcted heart: impli-
cations on stem cell survival and preservation of infarcted heart 
function. J Mol Med (Berl) 90:997–1010
 19. Liu JD, valencia-Sanchez MA, Hannon GJ, Parker R (2005) 
MicroRNA-dependent localization of targeted mRNAs to mam-
malian P-bodies. Nat Cell Biol 7(7):719–723
 20. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, 
enright AJ (2006) miRBase: microRNA sequences, targets and 
gene nomenclature. Nucleic Acids Res 34:D140–D144
 21. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mecha-
nism, and function. Cell 116:281–297
 22. Friedman Y, Balaga O, Linial M (2013) working together: 
combinatorial regulation by microRNAs. Adv exp Med Biol 
774:317–337
 23. Lim LP, Lau NC, Garrett-engele P, Grimson A, Schelter JM, 
Castle J et al (2005) Microarray analysis shows that some 
Author's personal copy
MicroRNAs in myocardial ischemia
1 3
microRNAs downregulate large numbers of target mRNAs. 
Nature 433:769–773
 24. Boettger T, Braun T (2012) A new level of complexity: the 
role of microRNAs in cardiovascular development. Circ Res 
110:1000–1013
 25. Divakaran v, Mann DL (2008) The emerging role of micro-
RNAs in cardiac remodeling and heart failure. Circ Res 
103(10):1072–1083
 26. Han M, Toli J, Abdellatif M (2011) MicroRNAs in the cardio-
vascular system. Curr Opin Cardiol 26:181–189
 27. Kukreja RC, Yin C, Salloum FN (2011) MicroRNAs: new play-
ers in cardiac injury and protection. Mol Pharmacol 80:558–564
 28. Ono K, Kuwabara Y, Han JH (2011) MicroRNAs and cardiovas-
cular diseases. FeBS J 278:1619–1633
 29. Zhao Y, Samal e, Srivastava D (2005) Serum response factor 
regulates a muscle-specific microRNA that targets Hand2 dur-
ing cardiogenesis. Nature 436:214–220
 30. Tatsuguchi M, Seok HY, Callis Te, Thomson JM, Chen JF, 
Newman M et al (2007) expression of microRNAs is dynami-
cally regulated during cardiomyocyte hypertrophy. J Mol Cell 
Cardiol 42:1137–1141
 31. van Rooij e, Sutherland LB, Liu N, williams AH, McAnally J, 
Gerard RD et al (2006) A signature pattern of stress-responsive 
microRNAs that can evoke cardiac hypertrophy and heart fail-
ure. Proc Natl Acad Sci USA 103:18255–18260
 32. van Rooij e, Sutherland LB, Qi XX, Richardson JA, Hill J, 
Olson eN (2007) Control of stress-dependent cardiac growth 
and gene expression by a microRNA. Science 316:575–579
 33. Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven 
wA, Bednarik D (2005) Mixed messages: transcription pat-
terns in failing and recovering human myocardium. Circ Res 
96:592–599
 34. Matkovich SJ, van Booven DJ, Youker KA, Torre-Amione G, 
Diwan A, eschenbacher wH et al (2009) Reciprocal regulation 
of myocardial microRNAs and messenger RNA in human car-
diomyopathy and reversal of the microRNA signature by bio-
mechanical support. Circulation 119:1263–1271
 35. Liu N, Olson eN (2010) MicroRNA regulatory networks in car-
diovascular development. Dev Cell 18:510–525
 36. Small eM, Frost RJA, Olson eN (2010) MicroRNAs add 
a new dimension to cardiovascular disease. Circulation 
121:1022–1032
 37. van Rooij e, Liu N, Olson eN (2008) MicroRNAs flex their 
muscles. Trends Genet 24:159–166
 38. van Rooij e, Quiat D, Johnson BA, Sutherland LB, Qi XX, 
Richardson JA et al (2009) A family of microRNAs encoded by 
myosin genes governs myosin expression and muscle perfor-
mance. Dev Cell 17:662–673
 39. Chen JF, Mandel eM, Thomson JM, wu QL, Callis Te, Ham-
mond SM et al (2006) The role of microRNA-1 and micro-
RNA-133 in skeletal muscle proliferation and differentiation. 
Nat Genet 38:228–233
 40. Czubryt MP, McAnally J, Fishman GI, Olson eN (2003) Regula-
tion of peroxisome proliferator-activated receptor gamma coac-
tivator 1 alpha (PGC-1 alpha) and mitochondrial function by 
MeF2 and HDAC5. Proc Natl Acad Sci USA 100:1711–1716
 41. Liu N, Bezprozvannaya S, williams AH, Qi XX, Richardson 
JA, Bassel-Duby R et al (2008) microRNA-133a regulates car-
diomyocyte proliferation and suppresses smooth muscle gene 
expression in the heart. Gene Dev 22:3242–3254
 42. McCarthy JJ, esser KA (2007) MicroRNA-1 and microRNA-
133a expression are decreased during skeletal muscle hypertro-
phy. J Appl Phys 102:306–313
 43. Hua Z, Lv Q, Ye wB, wong CKA, Cai GP, Gu DY et al (2006) 
miRNA-directed regulation of veGF and other angiogenic fac-
tors under hypoxia. PLoS ONe 1:e116
 44. Migliore C, Martin v, Leoni vP, Restivo A, Atzori L, Petrelli 
A et al (2012) MiR-1 downregulation cooperates with MACC1 
in promoting MeT overexpression in human colon cancer. Clin 
Cancer Res 18:737–747
 45. Leo C, Sala v, Morello M, Chiribiri A, Riess I, Mancardi D et al 
(2011) Activated Met signalling in the developing mouse heart 
leads to cardiac disease. PLoS ONe 6:e14675
 46. Sala v, Crepaldi T (2011) Novel therapy for myocardial 
infarction: can HGF/Met be beneficial? Cell Mol Life Sci 
68:1703–1717
 47. elia L, Contu R, Quintavalle M, varrone F, Chimenti C, Russo 
MA et al (2009) Reciprocal regulation of microRNA-1 and 
insulin-like growth factor-1 signal transduction cascade in car-
diac and skeletal muscle in physiological and pathological con-
ditions. Circulation 120:2377–2385
 48. Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, 
Nagalingam RS et al (2012) A novel cardiomyocyte-enriched 
microRNA, miR-378, targets insulin-like growth factor 1 recep-
tor Implications in postnatal cardiac remodeling and cell sur-
vival. J Biol Chem 287:12913–12926
 49. eltzschig HK, eckle T (2011) Ischemia and reperfusion-from 
mechanism to translation. Nat Med 17:1391–1401
 50. Oerlemans MIFJ, Koudstaal S, Chamuleau SA, de Kleijn DP, 
Doevendans PA, Sluijter JPG (2013) Targeting cell death in the 
reperfused heart: pharmacological approaches for cardioprotec-
tion. Int J Cardiol 165:410–422
 51. Xiao J, Zhu XY, He B, Zhang YF, Kang B, wang ZN et al 
(2011) miR-204 regulates cardiomyocyte autophagy induced by 
ischemia-reperfusion through LC3-II. J Biomed Sci 18:35
 52. wang JX, Jiao JQ, Li QA, Long B, wang K, Liu JP et al (2011) 
miR-499 regulates mitochondrial dynamics by targeting cal-
cineurin and dynamin-related protein-1. Nat Med 17:71–78
 53. Li JC, Donath S, Li YR, Qin D, Prabhakar BS, Li PF (2010) miR-
30 regulates mitochondrial fission through targeting p53 and the 
dynamin-related protein-1 pathway. PLoS Genet 6:e1000795
 54. Qian L, van Laake Lw, Huang Y, Liu SY, wendland MF, Sriv-
astava D (2011) miR-24 inhibits apoptosis and represses Bim in 
mouse cardiomyocytes. J exp Med 208:549–560
 55. Dong SM, Cheng YH, Yang J, Li JY, Liu XJ, wang XB et al 
(2009) MicroRNA expression signature and the role of micro-
RNA-21 in the early phase of acute myocardial infarction. J 
Biol Chem 284:29514–29525
 56. Li DF, Tian J, Guo X, Huang LM, Xu Y, wang CC et al (2012) 
Induction of microRNA-24 by HIF-1 protects against ischemic 
injury in rat cardiomyocytes. Physiol Res 61:555–565
 57. Cheng YH, Liu XJ, Zhang SO, Lin Y, Yang J, Zhang CX (2009) 
MicroRNA-21 protects against the H2O2-induced injury on car-
diac myocytes via its target gene PDCD4. J Mol Cell Cardiol 
47:5–14
 58. Cheng YH, Zhu P, Yang JA, Liu XJ, Dong SM, wang XB et al 
(2010) Ischaemic preconditioning-regulated miR-21 protects 
heart against ischaemia/reperfusion injury via anti-apoptosis 
through its target PDCD4. Cardiovasc Res 87:431–439
 59. Hu SJ, Huang M, Nguyen PK, Gong YQ, Li ZJ, Jia FJ et al 
(2011) Novel microRNA prosurvival cocktail for improving 
engraftment and function of cardiac progenitor cell transplanta-
tion. Circulation 124:S27–S34
 60. Meloni M, Marchetti M, Garner K, Littlejohns B, Sala-Newby 
G, Xenophontos N et al (2013) Local inhibition of micro-
RNA-24 improves reparative angiogenesis and left ventricle 
remodeling and function in mice with myocardial infarction. 
Mol Ther. doi:10.1038/mt.2013.89:
 61. Chan YC, Banerjee J, Choi SY, Sen CK (2012) miR-210: the 
master hypoxamir. Microcirculation 19:215–223
 62. Fasanaro P, D’Alessandra Y, Di Stefano v, Melchionna 
R, Romani S, Pompilio G et al (2008) MicroRNA-210 
Author's personal copy
V. Sala et al.
1 3
modulates endothelial cell response to hypoxia and inhibits 
the receptor tyrosine kinase ligand ephrin-A3. J Biol Chem 
283:15878–15883
 63. Mutharasan RK, Nagpal v, Ichikawa Y, Ardehali H (2011) 
microRNA-210 is upregulated in hypoxic cardiomyo-
cytes through Akt- and p53-dependent pathways and exerts 
cytoprotective effects. Am J Physiol Heart Circ Physiol 
301:H1519–H1530
 64. Hu SJ, Huang M, Li ZJ, Jia FJ, Ghosh ZM, Lijkwan MA et al 
(2010) MicroRNA-210 as a novel therapy for treatment of 
ischemic heart disease. Circulation 122:S124–S131
 65. Kim Hw, Haider HK, Jiang SJ, Ashraf M (2009) Ischemic 
preconditioning augments survival of stem cells via miR-210 
expression by targeting caspase-8-associated protein 2. J Biol 
Chem 284:33161–33168
 66. Chan SY, Zhang YY, Hemann C, Mahoney Ce, Zweier JL, Los-
calzo J (2009) MicroRNA-210 controls mitochondrial metabo-
lism during hypoxia by repressing the iron-sulfur cluster assem-
bly proteins ISCU1/2. Cell Metab 10:273–284
 67. Chen Z, Li Y, Zhang H, Huang P, Luthra R (2010) Hypoxia-
regulated microRNA-210 modulates mitochondrial func-
tion and decreases ISCU and COX10 expression. Oncogene 
29:4362–4368
 68. Favaro e, Ramachandran A, McCormick R, Gee H, Blancher 
C, Crosby M et al (2010) MicroRNA-210 regulates mitochon-
drial free radical response to hypoxia and krebs cycle in cancer 
cells by targeting iron sulfur cluster protein ISCU. PLoS ONe 
5:e10345
 69. Ren XP, wu JH, wang XH, Sartor MA, Qian J, Jones K et al 
(2009) MicroRNA-320 is involved in the regulation of cardiac 
ischemia/reperfusion injury by targeting heat-shock protein 20. 
Circulation 119:2357–2366
 70. Hermeking H (2007) p53 enters the microRNA world. Cancer 
Cell 12:414–418
 71. Bernardo BC, Gao XM, winbanks Ce, Boey eJH, Tham YK, 
Kiriazis H et al (2012) Therapeutic inhibition of the miR-34 
family attenuates pathological cardiac remodeling and improves 
heart function. Proc Natl Acad Sci USA 109:17615–17620
 72. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S 
et al (2013) MicroRNA-34a regulates cardiac ageing and func-
tion. Nature 495:107–110
 73. Ye YM, Hu ZY, Lin Y, Zhang CF, Perez-Polo JR (2010) Down-
regulation of microRNA-29 by antisense inhibitors and a 
PPAR-gamma agonist protects against myocardial ischaemia-
reperfusion injury. Cardiovasc Res 87:535–544
 74. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, 
Semus HM, Lynch JM et al (2012) Inhibition of miR-15 pro-
tects against cardiac ischemic injury. Circ Res 110:71–81
 75. Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN et al 
(2009) Upregulated expression of miR-1/miR-206 in a rat 
model of myocardial infarction. Biochem Bioph Res Co 
381:597–601
 76. Tang YH, Zheng JY, Sun Y, wu ZG, Liu ZM, Huang GZ (2009) 
MicroRNA-1 regulates cardiomyocyte apoptosis by targeting 
Bcl-2. Int Heart J 50:377–387
 77. Xu CQ, Lu YJ, Pan Zw, Chu wF, Luo XB, Lin HX et al (2011) 
The muscle-specific microRNAs miR-1 and miR-133 produce 
opposing effects on apoptosis by targeting HSP60, HSP70 and 
caspase-9 in cardiomyocytes. J Cell Sci 124:3187 (retraction of 
vol 120, p 3045, 2007)
 78. Fang J, Song Xw, Tian J, Chen HY, Li DF, wang JF et al (2012) 
Overexpression of microRNA-378 attenuates ischemia-induced 
apoptosis by inhibiting caspase-3 expression in cardiac myo-
cytes. Apoptosis 17:410–423
 79. wang XH, Zhang Xw, Ren XP, Chen J, Liu HZ, Yang JQ 
et al (2010) MicroRNA-494 targeting both proapoptotic and 
antiapoptotic proteins protects against ischemia/reperfusion-
induced cardiac injury. Circulation 122:1308–1318
 80. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M 
et al (2008) MicroRNA-21 contributes to myocardial disease 
by stimulating MAP kinase signaling in fibroblasts. Nature 
456:980–984
 81. Sayed D, Rane S, Lypowy J, He MZ, Chen IY, vashistha H et al 
(2008) MicroRNA-21 targets sprouty2 and promotes cellular 
outgrowths. Mol Biol Cell 19:3272–3282
 82. Bronnum H, Andersen DC, Schneider M, Sandberg MB, 
eskildsen T, Nielsen SB et al (2013) miR-21 promotes fibro-
genic epithelial-to-mesenchymal transition of epicardial meso-
thelial cells involving programmed cell death 4 and sprouty-1. 
PLoS ONe 8(2):e56280
 83. Roy S, Khanna S, Hussain SRA, Biswas S, Azad A, Rink C et al 
(2009) MicroRNA expression in response to murine myocardial 
infarction: miR-21 regulates fibroblast metalloprotease-2 via 
phosphatase and tensin homologue. Cardiovasc Res 82:21–29
 84. Patrick DM, Montgomery RL, Qi XX, Obad S, Kauppinen 
S, Hill JA et al (2010) Stress-dependent cardiac remodeling 
occurs in the absence of microRNA-21 in mice. J Clin Invest 
120:3912–3916
 85. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink v, van 
der Made I et al (2009) miR-133 and miR-30 regulate connec-
tive tissue growth factor Implications for a role of microRNAs 
in myocardial matrix remodeling. Circ Res 104:170–178
 86. van Rooij e, Sutherland LB, Thatcher Je, Dimaio JM, Naseem 
RH, Marshall wS et al (2008) Dysregulation of microRNAs 
after myocardial infarction reveals a role of miR-29 in cardiac 
fibrosis. Proc Natl Acad Sci USA 105:13027–13032
 87. Karakikes I (2013) Therapeutic cardiac-targeted delivery of 
miR-1 reverses pressure overload-induced cardiac hypertro-
phy and attenuates pathological remodeling. J Am Heart Assoc 
2(2):e000078
 88. Zhao N, Yu HY, Yu HT, Sun M, Zhang YY, Xu M et al (2013) 
miRNA-711-SP1-collagen-I pathway is involved in the anti-
fibrotic effect of pioglitazone in myocardial infarction. Sci 
China-Ser C 56:431–439
 89. Cushing L, Kuang PP, Qian J, Shao FZ, wu JJ, Little F et al 
(2011) miR-29 is a major regulator of genes associated with 
pulmonary fibrosis. Am J Resp Cell Mol Biol 45:287–294
 90. Kwiecinski M, Noetel A, elfimova N, Trebicka J, Schieven-
busch S, Strack I et al (2011) Hepatocyte growth factor (HGF) 
inhibits collagen I and Iv synthesis in hepatic stellate cells by 
miRNA-29 induction. PLoS ONe 6:e24568
 91. Liang HH, Zhang C, Ban T, Liu Y, Mei L, Piao XM et al (2012) 
A novel reciprocal loop between microRNA-21 and TGF 
beta RIII is involved in cardiac fibrosis. Int J Biochem Cell B 
44:2152–2160
 92. wang J, Huang wC, Xu RX, Nie Y, Cao XQ, Meng J et al 
(2012) MicroRNA-24 regulates cardiac fibrosis after myocar-
dial infarction. J Cell Mol Med 16:2150–2160
 93. Pan Zw, Sun XL, Shan HL, wang N, wang JH, Ren JS et al 
(2012) MicroRNA-101 inhibited postinfarct cardiac fibrosis and 
improved left ventricular compliance via the FBJ osteosarcoma 
oncogene/transforming growth factor-beta 1 pathway. Circula-
tion 126:840–850
 94. Yamakuchi M (2013) MicroRNAs in vascular biology. Int J 
vasc Med. doi:10.1155/2012/794898
 95. wang SS, Aurora AB, Johnson BA, Qi XX, McAnally J, Hill JA 
et al (2008) The endothelial-specific microRNA miR-126 gov-
erns vascular integrity and angiogenesis. Dev Cell 15:261–271
 96. van Mil A, vrijsen KR, Goumans MJ, Metz CH, Doevendans 
PA, Sluijter JP (2013) MicroRNA-1 enhances the angiogenic 
differentiation of human cardiomyocyte progenitor cells. J Mol 
Med 91(8):1001–1012
Author's personal copy
MicroRNAs in myocardial ischemia
1 3
 97. Chen JJ, Zhou SH (2011) Mesenchymal stem cells overexpress-
ing MiR-126 enhance ischemic angiogenesis via the AKT/
eRK-related pathway. Cardiol J 18:675–681
 98. Huang F, Zhu X, Hu XQ, Fang ZF, Tang L, Lu XL et al (2013) Mes-
enchymal stem cells modified with miR-126 release angiogenic 
factors and activate Notch ligand Delta-like-4, enhancing ischemic 
angiogenesis and cell survival. Int J Mol Med 31:484–492
 99. Jakob P, Doerries C, Briand S, Mocharla P, Krankel N, Besler 
C et al (2012) Loss of AngiomiR-126 and 130a in angiogenic 
early outgrowth cells from patients with chronic heart failure 
Role for impaired in vivo neovascularization and cardiac repair 
capacity. Circulation 126:2962–2975
 100. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, 
Fischer A et al (2009) MicroRNA-92a controls angiogenesis 
and functional recovery of ischemic tissues in mice. Science 
324:1710–1713
 101. Fiedler J, Jazbutyte v, Kirchmaier BC, Gupta SK, Lorenzen J, 
Hartmann D et al (2011) MicroRNA-24 regulates vascularity 
after myocardial infarction. Circulation 124:720–730
 102. van Mil A, Grundmann S, Goumans MJ, Lei ZY, Oerlemans 
MI, Jaksani S et al (2012) MicroRNA-214 inhibits angiogenesis 
by targeting Quaking and reducing angiogenic growth factor 
release. Cardiovasc Res 93:655–665
 103. Ikeda S, Pu wT (2010) expression and function of microRNAs 
in heart disease. Curr Drug Targets 11:913–925
 104. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M (2007) 
MicroRNAs play an essential role in the development of cardiac 
hypertrophy. Circ Res 100:416–424
 105. Sucharov C, Bristow MR, Port JD (2008) miRNA expression in 
the failing human heart: functional correlates. J Mol Cell Car-
diol 45:185–192
 106. Thum T, Galuppo P, wolf C, Fiedler J, Kneitz S, van Laake Lw 
et al (2007) MicroRNAs in the human heart: a clue to fetal gene 
reprogramming in heart failure. Circulation 116:258–267
 107. Reddy S, Zhao MM, Hu DQ, Fajardo G, Hu SJ, Ghosh Z et al 
(2012) Dynamic microRNA expression during the transition 
from right ventricular hypertrophy to failure. Physiol Genomics 
44:562–575
 108. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski 
B et al (2011) Calcium upregulation by percutaneous adminis-
tration of gene therapy in cardiac disease (CUPID) a phase 2 
trial of intracoronary gene therapy of sarcoplasmic reticulum 
Ca2+-ATPase in patients with advanced heart failure. Circula-
tion 124:304–313
 109. Kumarswamy R, Lyon AR, volkmann I, Mills AM, Bretthauer 
J, Pahuja A et al (2012) SeRCA2a gene therapy restores micro-
RNA-1 expression in heart failure via an Akt/FoxO3A-depend-
ent pathway. eur Heart J 33:1067–1075
 110. Ikeda S, He AB, Kong Sw, Lu J, Bejar R, Bodyak N et al 
(2009) MicroRNA-1 negatively regulates expression of the 
hypertrophy-associated calmodulin and Mef2a genes. Mol Cell 
Biol 29:2193–2204
 111. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P 
et al (2007) MicroRNA-133 controls cardiac hypertrophy. Nat 
Med 13:613–618
 112. Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij e, 
Matsuzaki S et al (2012) MicroRNA-214 protects the mouse 
heart from ischemic injury by controlling Ca2+ overload and 
cell death. J Clin Invest 122:1222–1232
 113. Cha MJ (2013) MicroRNA-145 suppresses ROS-induced Ca(2+) 
overload of cardiomyocytes by targeting CaMKII? Biochem 
Biophys Res Commun 435:720–726
 114. Li RT, Yan GJ, Li QL, Sun HX, Hu YL, Sun JX et al (2012) 
MicroRNA-145 protects cardiomyocytes against hydrogen 
peroxide (H2O2)-induced apoptosis through targeting the mito-
chondria apoptotic pathway. PLoS ONe 7:e44907
 115. van Mil A, Grundmann S, Goumans MJ, Lei ZY, Oerlemans 
MI, Jaksani S et al (2012) MicroRNA-214 inhibits angiogenesis 
by targeting Quaking and reducing angiogenic growth factor 
release. Cardiovasc Res 93:655–665
 116. Mitchell PS, Parkin RK, Kroh eM, Fritz BR, wyman SK, 
Pogosova-Agadjanyan eL et al (2008) Circulating microRNAs 
as stable blood-based markers for cancer detection. Proc Natl 
Acad Sci USA 105:10513–10518
 117. Tijsen AJ, Creemers ee, Moerland PD, De windt LJ, van der 
wal AC, Kok we et al (2010) MiR423-5p as a circulating bio-
marker for heart failure. Circ Res 106:1035–1039
 118. Kumarswamy R, Thum T, Anker SD (2010) MicroRNAs as 
circulating biomarkers for heart failure: questions about MiR-
423-5p. Circ Res 106:e8
 119. wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J et al (2010) 
Circulating microRNA: a novel potential biomarker for early 
diagnosis of acute myocardial infarction in humans. eur Heart J 
31:659–666
 120. Ai J, Zhang R, Li Y, Pu JL, Lu YJ, Jiao JD et al (2010) Cir-
culating microRNA-1 as a potential novel biomarker for acute 
myocardial infarction.   Biochem Biophys Res Communn 
391:73–77
 121. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, 
Hofstra L et al (2010) Circulating microRNA-208b and micro-
RNA-499 reflect myocardial damage in cardiovascular disease. 
Circ Cardiovasc Gene 3:499–506
 122. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M 
et al (2011) Increased MicroRNA-1 and MicroRNA-133a levels 
in serum of patients with cardiovascular disease indicate myo-
cardial damage. Circ Cardiovasc Gene 4:446–454
 123. Long Gw, wang F, Duan QL, Yang SL, Chen FQ, Gong w et al 
(2012) Circulating miR-30a, miR-195 and let-7b associated 
with acute myocardial infarction. PLoS ONe 7:e24568
 124. Oerlemans MIFJ, Mosterd A, Dekker MS, de vrey eA, van Mil 
A, Pasterkamp G et al (2012) early assessment of acute coro-
nary syndromes in the emergency department: the potential 
diagnostic value of circulating microRNAs. eMBO Mol Med 
4:1176–1185
 125. Abdellatif M (2012) Differential expression of microRNAs in 
different disease states. Circ Res 110:638–650
 126. Cai BZ, Pan Zw, Lu YJ (2010) The roles of microRNAs in 
heart diseases: a novel important regulator. Curr Med Chem 
17:407–411
 127. Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F (2010) 
MicroRNA: emerging therapeutic targets in acute ischemic dis-
eases. Pharmacol Therap 125:92–104
 128. Frost RJA, van Rooij e (2010) miRNAs as therapeutic targets in 
ischemic heart disease. J Cardiovasc Transl Res 3:280–289
 129. Heyn J, Hinske C, Mohnle P, Luchting B, Beiras-Fernandez A, 
Kreth S (2011) MicroRNAs as potential therapeutic agents in 
the treatment of myocardial infarction. Curr vasc Pharmacol 
9:733–740
 130. Montgomery RL, van Rooij e (2010) MicroRNA regulation as 
a therapeutic strategy for cardiovascular disease. Curr Drug Tar-
gets 11:936–942
 131. van Rooij e, Purcell AL, Levin AA (2012) Developing micro-
RNA therapeutics. Circ Res 110:496–507
 132. Bish LT, Morine K, Sleeper MM, Sanmiguel J, wu D, Gao GP 
et al (2008) Adeno-associated virus (aav) serotype 9 provides 
global cardiac gene transfer superior to AAv1, AAv6, AAv7, 
and AAv8 in the mouse and rat. Hum Gene Ther 19:1359–1368
 133. Rane S, He MZ, Sayed D, vashistha H, Malhotra A, Sad-
oshima J et al (2009) Downregulation of MiR-199a derepresses 
hypoxia-inducible factor-1 alpha and sirtuin 1 and recapitu-
lates hypoxia preconditioning in cardiac myocytes. Circ Res 
104:879–886
Author's personal copy
V. Sala et al.
1 3
 134. Chan YC, Roy S, Huang Y, Khanna S, Sen CK (2012) The 
microRNA miR-199a-5p down-regulation switches on wound 
angiogenesis by derepressing the v-ets erythroblastosis virus 
e26 oncogene homolog 1-matrix metalloproteinase-1 pathway. 
J Biol Chem 287:41032–41043
 135. Ahuja P, Sdek P, MaClellan wR (2007) Cardiac myocyte cell 
cycle control in development, disease, and regeneration. Physiol 
Rev 87:521–544
 136. Collesi C, Zentilin L, Sinagra G, Giacca M (2008) Notch1 sign-
aling stimulates proliferation of immature cardiomyocytes. J 
Cell Biol 183:117–128
 137. Li FQ, wang XJ, Capasso JM, Gerdes AM (1996) Rapid transi-
tion of cardiac myocytes from hyperplasia to hypertrophy dur-
ing postnatal development. J Mol Cell Cardiol 28:1737–1746
 138. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ (1996) 
Cardiomyocyte DNA synthesis and binucleation during murine 
development. Am J Physiol-Heart C 271:H2183–H2189
 139. Bicknell KA, Coxon CNH, Brooks G (2007) Can the car-
diomyocyte cell cycle be reprogrammed? J Mol Cell Cardiol 
42:706–721
 140. Senyo Se, Steinhauser ML, Pizzimenti CL, Yang vK, Cai L, 
wang M et al (2013) Mammalian heart renewal by pre-existing 
cardiomyocytes. Nature 493(7432):433–436
 141. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani 
R et al (2001) evidence that human cardiac myocytes divide 
after myocardial infarction. New engl J Med 344:1750–1757
 142. Kajstura J, Zhang X, Reiss K, Szoke e, Li P, Lagrasta C et al 
(1994) Myocyte cellular hyperplasia and myocyte cellular 
hypertrophy contribute to chronic ventricular remodeling in 
coronary-artery narrowing-induced cardiomyopathy in rats. 
Circ Res 74:383–400
 143. Reiss K, Kajstura J, Capasso JM, Marino TA, Anversa P (1993) 
Impairment of myocyte contractility following coronary-artery 
narrowing is associated with activation of the myocyte Igf(1) 
autocrine system, enhanced expression of late growth-related 
genes, dna-synthesis, and myocyte nuclear mitotic division in 
rats. exp Cell Res 207:348–360
 144. Porrello eR, Johnson BA, Aurora AB, Simpson e, Nam YJ, 
Matkovich SJ et al (2011) miR-15 family regulates postnatal 
mitotic arrest of cardiomyocytes. Circ Res 109:670–679
 145. Porrello eR, Mahmoud AI, Simpson e, Johnson BA, Grins-
felder D, Canseco D et al (2013) Regulation of neonatal and 
adult mammalian heart regeneration by the miR-15 family. Proc 
Natl Acad Sci USA 110:187–192
 146. Zhao Y, Ransom JF, Li A, vedantham v, von Drehle M, Muth 
AN et al (2007) Dysregulation of cardiogenesis, cardiac con-
duction, and cell cycle in mice lacking miRNA-1-2. Cell 
129:303–317
 147. Yin vP, Lepilina A, Smith A, Poss KD (2012) Regula-
tion of zebrafish heart regeneration by miR-133. Dev Biol 
365:319–327
 148. Jopling C, Sleep e, Raya M, Marti M, Raya A, Belmonte JCI 
(2010) Zebrafish heart regeneration occurs by cardiomyocyte 
dedifferentiation and proliferation. Nature 464(7288):606–609
 149. Kikuchi K, Holdway Je, werdich AA, Anderson RM, Fang Y, 
egnaczyk GF et al (2010) Primary contribution to zebrafish 
heart regeneration by gata4(+)
 cardiomyocytes. Nature 
464:601–605
 150. Poss KD, Nechiporuk A, Hillam AM, Johnson SL, Keating MT 
(2002) Mps1 defines a proximal blastemal proliferative com-
partment essential for zebrafish fin regeneration. Development 
129:5141–5149
 151. Chen J, Huang ZP, Seok HY, Ding J, Kataoka M, Zhang Z et al 
(2013) Mir-17-92 cluster is required for and sufficient to induce 
cardiomyocyte proliferation in postnatal and adult hearts. Circ 
Res 112:1557–1566
 152. eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zac-
chigna S et al (2012) Functional screening identifies miRNAs 
inducing cardiac regeneration. Nature 492:376–381
 153. Porrello eR (2013) microRNAs in cardiac development and 
regeneration. Clin Sci (Lond) 125:151–166
 154. Srivastava D (2013) Small solutions to big problems: micrornas 
for cardiac regeneration. Circ Res 112:1412–1414
 155. van Amerongen MJ, engel FB (2008) Features of cardiomyo-
cyte proliferation and its potential for cardiac regeneration. J 
Cell Mol Med 12:2233–2244
 156. Anversa P, Nadal-Ginard B (2002) Myocyte renewal and ven-
tricular remodelling. Nature 415:240–243
 157. van vliet P, Roccio M, Smits AM, van Oorschot AAM, Metz 
CHG, van veen TAB et al (2008) Progenitor cells isolated from 
the human heart: a potential cell source for regenerative therapy. 
Neth Heart J 16:163–169
 158. Segers vFM, Lee RT (2008) Stem-cell therapy for cardiac dis-
ease. Nature 451:937–942
 159. Kuppusamy KT (2013) MicroRNA regulation and role in stem 
cell maintenance, cardiac differentiation and hypertrophy. Curr 
Mol Med 13:757–764
 160. Scott e (2013) miRNA regulation of endothelial homeostasis 
and commitment: implications for vascular regeneration strate-
gies using stem cell therapies. Free Radic Biol Med (in press)
 161. Brás-Rosário L, Matsuda A, Pinheiro AI, Gardner R, Lopes 
T, Amaral A, Gama-Carvalho M (2013) expression profile 
of microRNAs regulating proliferation and differentiation in 
mouse adult cardiac stem cells. PLoS ONe 8(5):e63041
 162. Sirish P, Lopez Je, Li N, wong A, Timofeyev v, Young JN et al 
(2012) MicroRNA profiling predicts a variance in the prolifera-
tive potential of cardiac progenitor cells derived from neonatal 
and adult murine hearts. J Mol Cell Cardiol 52:264–272
 163. Xiao JJ, Liang DD, Zhang H, Liu Y, Zhang DS, Liu Y et al 
(2012) MicroRNA-204 is required for differentiation of human-
derived cardiomyocyte progenitor cells. J Mol Cell Cardiol 
53:751–759
 164. Heinrich eM, Dimmeler S (2012) MicroRNAs and stem cells 
control of pluripotency, reprogramming, and lineage commit-
ment. Circ Res 110:1014–1022
Author's personal copy
